Eli Lilly (LLY) and BioArctic AB Enter into Research and Collaboration Agreement
Key takeaways
- The company will also be entitled to tiered mid-single-digit royalties on future global product sales if the product reaches the market.
- It added that full responsibility for the global development and commercialization of the drug candidate and related products will be assumed by Eli Lilly and Company (NYSE:LLY).
- Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products.
Eli Lilly (LLY) and Bio Arctic AB Enter into Research and Collaboration Agreement Noor Ul Ain Rehman Sun, June 28, 2026 at 2:21 AM GMT+7 1 min read LLY BIOA-B.ST Eli Lilly and Company (NYSE:LLY) is one of the top trending US stocks to buy now. Eli Lilly and Company (NYSE:LLY) and Bio Arctic AB announced on June 22 their entry into a research and collaboration agreement regarding a potential new treatment combining Bio Arctic's proprietary Brain Transporter technology with an undisclosed Lilly drug candidate in neurodegeneration. Management stated that BioArctic will receive USD 30 million in upfront payment as part of the agreement, and will be eligible to receive additional milestone payments of up to USD 770 million in addition to the upfront payment. The company will also be entitled to tiered mid-single-digit royalties on future global product sales if the product reaches the market.
Eli Lilly and Company (NYSE:LLY) further reported that under the terms of the collaboration, BioArctic will generate a new drug candidate by bringing together the BrainTransporter technology with a Lilly proprietary molecule. It added that full responsibility for the global development and commercialization of the drug candidate and related products will be assumed by Eli Lilly and Company (NYSE:LLY).
Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span oncology, diabetes, immunology, neuroscience, and other therapies.